RNA based vaccine · VDDBV0500
Note: 3 additional source trials listed this vaccine in studies of unrelated viruses (e.g. as a comparator, adjunct, or in coadministration trials with other vaccines). Those trials are not shown here.
| NCT ID | Phase | Disease / Condition |
|---|---|---|
| NCT04283461 | Phase 1 | COVID-19 |
| NCT04839315 | Phase 1 | COVID-19 |
| NCT04677660 | Phase 2 | COVID-19 |
| NCT04712110 | Phase 2 | COVID-19 |
| NCT04889209 | Phase 2 | COVID-19 |
| NCT05280158 | Phase 2 | COVID-19 |
| NCT04405076 | Phase 2 | COVID-19 |
| NCT05315362 | Phase 2 | COVID-19 |
| NCT05289037 | Phase 2 | COVID-19 |
| NCT04761822 | Phase 2 | COVID-19 |
| NCT04894435 | Phase 2 | COVID-19 |
| NCT04930770 | Phase 2 | COVID-19 |
| NCT04969263 | Phase 2 | COVID-19 |
| NCT05077254 | Phase 2 | COVID-19 |
| NCT05137236 | Phase 2 | COVID-19 |
| NCT05137236 | Phase 2 | COVID-19 |
| NCT05197153 | Phase 2 | COVID-19 |
| NCT04649151 | Phase 3 | COVID-19 |
| NCT04796896 | Phase 3 | COVID-19 |
| NCT05022329 | Phase 3 | COVID-19 |
| NCT05168813 | Phase 3 | COVID-19 |
| NCT05236491 | Phase 3 | COVID-19 |
| NCT05249829 | Phase 3 | COVID-19 |
| NCT05279365 | Phase 3 | COVID-19 |
| NCT04470427 | Phase 3 | COVID-19 |
| NCT04811664 | Phase 3 | COVID-19 |
| NCT05299359 | Phase 3 | COVID-19 |
| NCT04805125 | Phase 3 | COVID-19 |
| NCT04806113 | Phase 3 | COVID-19 |
| NCT04860297 | Phase 3 | COVID-19 |
| NCT05048940 | Phase 3 | COVID-19 |
| NCT05119855 | Phase 3 | COVID-19 |
| NCT05142319 | Phase 3 | COVID-19 |
| NCT05158140 | Phase 3 | COVID-19 |
| NCT05230953 | Phase 3 | COVID-19 |
| NCT04760132 | Approved | COVID-19 |
| NCT05060991 | Approved | COVID-19 |
| NCT04792567 | Approved | COVID-19 |
| NCT04885907 | Approved | COVID-19 |
| NCT04952402 | Approved | COVID-19 |
| NCT04969250 | Approved | COVID-19 |
| NCT05030974 | Approved | COVID-19 |
| NCT05047718 | Approved | COVID-19 |
| NCT05079633 | Approved | COVID-19 |
| NCT05075538 | Approved | COVID-19 |
| NCT05075538 | Approved | COVID-19 |
| NCT05160766 | Approved | COVID-19 |